基础胰岛素控制不佳的2型糖尿病进阶治疗:SoliMix试验中iGlarLixi与预混BIAsp 30的临床结局比较
SoliMix是一项26周开放标签多中心随机对照试验,纳入基础胰岛素联合口服降糖药控制不佳的2型糖尿病患者,比较每日一次iGlarLixi与每日两次预混BIAsp 30的疗效与安全性。结果显示iGlarLixi在HbA1c降幅上非劣于且优效于BIAsp 30,体重变化更优,低血糖发生率更低。
要点
- iGlarLixi在HbA1c降幅上非劣于且优效于BIAsp 30。
- iGlarLixi体重变化优于BIAsp 30,低血糖发生率更低。
- iGlarLixi可作为基础胰岛素联合OAD控制不佳时更有效、简便的替代方案。
核心结论
- 每日一次iGlarLixi较每日两次预混BIAsp 30提供更好的血糖控制、体重获益且低血糖更少。
- iGlarLixi是基础胰岛素联合OAD治疗仍不达标时更有效、更简便且耐受良好的替代选择。
研究设计与样本
- SoliMix为26周、开放标签、多中心随机对照试验。
- 纳入基础胰岛素联合口服降糖药控制不佳的成人2型糖尿病患者,HbA1c≥7.5%且≤10%,随机接受每日一次iGlarLixi或每日两次BIAsp 30。
- 主要疗效终点为HbA1c降幅的非劣性(界值0.3%)或体重变化的优效性。
主要发现
- 26周后,基线HbA1c 8.6%在iGlarLixi组降低1.3%,BIAsp 30组降低1.1%,达到非劣性(最小二乘均值差-0.2% [97.5% CI -0.4, -0.1];P < 0.001)。
- iGlarLixi在体重变化上优于BIAsp 30(最小二乘均值差-1.9 kg [95% CI -2.3, -1.4])。
- iGlarLixi在HbA1c降幅上优于BIAsp 30(P < 0.001)。
- 达到HbA1c <7%且无体重增加、以及HbA1c <7%且无体重增加且无低血糖的参与者百分比,iGlarLixi均优于BIAsp 30(所有P < 0.001)。
- 美国糖尿病协会1级和2级低血糖的发生率和事件率在iGlarLixi组低于BIAsp 30组。
临床怎么用
- 对于基础胰岛素联合OAD控制不佳的2型糖尿病患者,可考虑每日一次iGlarLixi作为进阶治疗。
- iGlarLixi相比每日两次预混BIAsp 30可能提供更好的血糖控制、体重获益和更低的低血糖风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30) as treatment advancement in type 2 diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: In SoliMix, a 26-week, open-label, multicenter study, adults with suboptimally controlled basal insulin-treated type 2 diabetes (HbA1c ≥7.5% and ≤10%) were randomized to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy end points were noninferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. RESULTS: Both primary efficacy end points were met: after 26 weeks, baseline HbA1c (8.6%) was reduced by 1.3% with iGlarLixi and 1.1% with BIAsp 30, meeting noninferiority (least squares [LS] mean difference -0.2% [97.5% CI -0.4, -0.1]; P < 0.001). iGlarLixi was also superior to BIAsp 30 for body weight change (LS mean difference -1.9 kg [95% CI -2.3, -1.4]) and percentage of participants achieving HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycemia (all P < 0.001). iGlarLixi was also superior versus BIAsp 30 for HbA1c reduction (P < 0.001). Incidence and rates of American Diabetes Association level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30. CONCLUSIONS: Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy.
引用
- Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care. 2021. PMID: 34183429. doi:10.2337/dc21-0393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。